BIOLIFE SOLUTIONS INC — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 88/100
What the filing says
On July 21, 2026, Repligen agreed to acquire BioLife Solutions for ~$1.5 billion enterprise value ($11.25 cash + 0.1442 Repligen shares per BioLife share), with closing expected Q4 2026. BioLife reported Q2 2026 revenue of $28.5M (+21% vs Q2 2025), adjusted EBITDA of $7.4M (26% margin), and adjusted net income of $4.2M (excluding $42.4M non-cash tax benefit). BioLife's biopreservation media holds ~70% market share in ~250 ongoing CGT trials and is embedded in 18 approved therapies.
Why this rating
Acquisition at ~1.78x revenue (for $845M market-cap company) eliminates independence; transformational M&A event materially alters company trajectory—shareholders' ownership converts to mixed consideration. High relative deal size materially restructures enterprise.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.